SGLT2 inhibitors have substantial beneficial effects on renal and cardiac function in patients with heart failure (McMurray et al., 2019; Packer et al., 2020; Anker et al., 2021) and patients with a wide spectrum of different chronic kidney diseases (CKD) (Heerspink et al., 2020; Herrington et al., 2022). This evidence concerns the gene SLC5A2 and chronic kidney disease.